It is our top pick. I like the lack of patent expirations.. They have a portfolio of new products.
Chris Schott
The company is not without controversy.
controversy company
A lack of mergers has allowed them to stay focused on strategy, Their alliances have been a success.
strategy success lack
We view this as a critical event in the Pfizer story and a potential positive catalyst for the stock.
potential positive story critical view
products lack
We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company.
direction company sign view
Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's billion cost restructuring will stabilize near-term earnings.
growth times expectations opinion view
I think Hank's credibility has been hurt but I think he has admitted that. I think he needs to be upfront about how they are handling all the variables facing the business.
business hurt
You must log in to post a comment.
There are no comments yet.